- Conditions
- Bladder Cancer
- Interventions
- gemcitabine hydrochloride, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 70
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 44 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 7,248
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumonia, Bacterial
- Interventions
- Ceftriaxone, beta-lactam
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 6
- States / cities
- New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 3 more
- Conditions
- Oral Mucositis
- Interventions
- ALD518, 0.9% saline
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more
- Conditions
- Solid Tumor, Adult
- Interventions
- BGB-24714, Paclitaxel, Carboplatin, Docetaxel
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Sarasota, Florida • St. Petersburg, Florida + 12 more
- Conditions
- Acute, Uncomplicated Human Influenza
- Interventions
- Peramivir, Placebo
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 58 more
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- OPN-6602, Dexamethasone
- Drug
- Lead sponsor
- Opna Bio LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 12
- States / cities
- Gilbert, Arizona • La Jolla, California • Stanford, California + 9 more
- Conditions
- Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
- Interventions
- zenocutuzumab (MCLA-128)
- Drug
- Lead sponsor
- Partner Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Cerritos, California • Irvine, California + 21 more
- Conditions
- Uveitis
- Interventions
- Izokibep, Placebo
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
- Conditions
- Leukemia
- Interventions
- imatinib mesylate, tanespimycin
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Peripheral Artery Disease, Overweight or Obesity
- Interventions
- Weight loss, Exercise
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • New Orleans, Louisiana • Baltimore, Maryland + 3 more
- Conditions
- Acute Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,805 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Chicago, Illinois + 10 more
- Conditions
- Central Retinal Artery Occlusion
- Interventions
- KUS121 high dose, KUS121 low dose, Sham procedure
- Drug
- Lead sponsor
- Kyoto Drug Discovery and Development Co., Ltd.
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 11
- States / cities
- Encino, California • Huntington Beach, California • Oakland, California + 8 more
- Conditions
- Neoplasms
- Interventions
- MK-0482, pembrolizumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pemetrexed
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Hackensack, New Jersey • San Antonio, Texas
- Conditions
- Chronic HBV Infection
- Interventions
- GS-4774, OAV Regimen
- Biological · Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Pasadena, California • Sacramento, California + 13 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus], Pioglitazone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more
- Conditions
- Primary Biliary Cholangitis, Primary Biliary Cirrhosis, Cholangitis, Cholestasis, Biliary Tract Diseases, Bile Duct Stricture
- Interventions
- HTD1801 (BUDCA)
- Drug
- Lead sponsor
- HighTide Therapeutics (Hong Kong) Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 12
- States / cities
- Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 9 more
- Conditions
- Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 11,196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2023
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 141 more
- Conditions
- Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)
- Interventions
- KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel
- Biological · Drug
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Dothan, Alabama • Scottsdale, Arizona • Beverly Hills, California + 11 more
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
- Interventions
- MRTX849, Pembrolizumab, Cetuximab, Afatinib
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 221
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 156 more
- Conditions
- Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
- Interventions
- Cemsidomide, Dexamethasone
- Drug
- Lead sponsor
- C4 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
- Interventions
- fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy
- Radiation · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 20 Years to 59 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Obesity
- Interventions
- pramlintide acetate, placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 21
- States / cities
- Chula Vista, California • San Diego, California • Walnut Creek, California + 18 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Comparison between GenePOC PCR and Reference Method
- Device
- Lead sponsor
- Meridian Bioscience, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Detroit, Michigan + 2 more